Navigation Links
Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres
Date:1/19/2010

ATLANTA, Jan. 19 /PRNewswire/ -- Professor Franco Orsi, MD, Medical Director of the Unit of Interventional Radiology at the European Institute of Oncology was awarded The Symposium on Clinical Interventional Oncology 2010 Best Poster Award by Dr. Shaun Samuels, Lead Course Director, for his poster presentation entitled; Micro-Bland Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic Tumors.

Orsi's poster as well as an oral abstract, were presented to a capacity audience at this year's Pre-ISET Course, Clinical Interventional Cardiology (CIO), in Hollywood, Florida.  

In 18 patients affected by single unresectable liver tumors or unwilling to be resected, Orsi used a combination therapy of radiofrequency ablation (RFA) immediately after micro-bland transhepatic arterial embolization (MBTAE).   The technique pioneered by Orsi and the group at the European Institute of Oncology has demonstrated precise and ample tumor control.  During the procedure 40 and/or 100 micron Embozene Microspheres are used to block the micro vessels that supply blood to the tumors causing an additional reduction in tumor size by eliminating the blood supply and thermal dispersion.  Orsi's team then follows this with RFA.  In this combined procedure, the use of Embozene Microspheres has proven to increase the success and overcome previous limitations associated with RFA.

Orsi went on to state that technical success was achieved in all patients, with excellent results. All patients are alive and all tumor volumes have decreased within very safe margins.  Orsi's poster concluded to state that MBTAE has been carried out only with very small micro-spheres in order to induce a deep parenchymal ischemia for enhancing the thermal effect by RFA.  Combined therapy, in our series, has improved local results, allowing for a radical ablation of the so called "complex liver lesions". However, the series is limited and further prospective studies are needed for validating the combined approach.  

About Embozene Microspheres: Embozene Microspheres are the only microspheres offering 10 tightly calibrated sizes, each color-enhanced with a different color for increased procedural safety. They are composed of a hydrogel core and an exterior shell of Polyzene®-F, CeloNova's proprietary polymer which is proven to be anti-inflammatory and bacterial-resistant. Embozene Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. The 75, 1100, and 1300 micron sizes are not yet available in the US.

About CeloNova BioSciences: CeloNova develops novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment. The Company's current products include Embozene™ Color-Advanced Microspheres and the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. For more information, visit www.celonova.com.

SOURCE CeloNova BioSciences

RELATED LINKS
http://www.celonova.com

'/>"/>

SOURCE CeloNova BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. €1.6 million ($2.32 million) grant awarded to Prof. Kobi Rosenblum for brain and memory research
2. Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens
3. TeamStaff Awarded $3.3 Million Contract
4. pcRUSH.com / Atman, Inc. is Awarded General Services Administration (GSA) Schedule (GS-35F-0099W)
5. $12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP)
6. Jefferson awarded multi-million dollar NIH grant
7. Drummond Group Awarded DOE Funds for Texas Wind Integration Project
8. Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval
9. UM Clinical Research Building awarded prestigious LEED Building Certification
10. Turkey Genome Sequencing Consortium awarded $0.9 million from USDA
11. Acclaimed American Journalist Awarded Excellence In Journalism by American Society of Tropical Medicine and Hygiene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although ... the majority of skin cancer deaths. More than 10,000 people are expected to die of ... is 62, it is the one of the most commonly diagnosed cancers in young women. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... India , April 28, 2016 ... Pipeline Review, H1 2016" is a report that ... and helps strengthen R&D pipelines by identifying new ... products. Company Profiles discussed in this ... Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
Breaking Medicine Technology: